Beam Gets Important Proof Of Concept For AATD Therapy
The company announced early proof-of-concept data for BEAM-302, its base-editing medicine for the genetic liver and lung disease alpha-1 antitrypsin deficiency, showing a clean safety profile.
The company announced early proof-of-concept data for BEAM-302, its base-editing medicine for the genetic liver and lung disease alpha-1 antitrypsin deficiency, showing a clean safety profile.